Abstract
Zoledronic acid (ZA) delays the onset or reduces the incidence of skeletal complications in breast cancer patients with bone metastases. However, there are few data on the long-term renal safety of ZA. We retrospectively evaluated 43 breast cancer patients with bone metastases who received ZA more than 24 months. The following parameters measured prior to first ZA use and after the last dose of ZA administration were compared: serum creatinine (SCr), blood urea nitrogen (BUN), alkaline phosphatase (ALP), calcium (Ca), and phosphorous (P). Forty-three breast cancer patients with documented bone metastases were evaluated. Median age at the start of treatment was 53 years (range 37-77). Median overall duration of ZA administration was 36 months (25-62). There were no statistically significant differences in the pre- and post-treatment levels of SCr, BUN, Ca and P. However, ALP levels after long-term ZA administration were decreased significantly (P<0.05). More than 24 months of ZA administration did not adversely affect the renal function. ZA can be used safely in breast cancer patients with bone metastases beyond 2 years.
References
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Feb 26, 1983·Lancet·H M BounameauxF Chatelanat
Dec 20, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·N ZojerM Pecherstorfer
May 25, 2001·Journal of the American Society of Nephrology : JASN·Glen S MarkowitzVivette D D'Agati
Jun 22, 2001·Cancer Treatment Reviews·R E Coleman
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M AliA Lipton
Jun 6, 2003·Kidney International·Glen S MarkowitzVivette D D'Agati
Sep 26, 2003·The New England Journal of Medicine·Bernard S Chang, Daniel H Lowenstein
Oct 24, 2003·The New England Journal of Medicine·Jennie T ChangJulie Beitz
Oct 27, 2004·Medical Hypotheses·Ozden AltundagIbrahim Gullu
Feb 19, 2005·Current Treatment Options in Oncology·Allan Lipton
Apr 27, 2005·The Oncologist·József Balla
Jul 22, 2005·The Cochrane Database of Systematic Reviews·N PavlakisM Stockler
Nov 30, 2005·The Oncologist·Valentina GuarneriPier Franco Conte
Mar 21, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T Tanvetyanon, P J Stiff
Jul 11, 2006·BMC Cancer·Klaartje MandersAdri C Voogd
Nov 4, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D Aguiar BujandaJ Aguiar Morales
May 4, 2007·Clinical Nephrology·N GokdenJ Kumar
Citations
May 28, 2009·Medical Oncology·Sercan AksoyKadri Altundag
May 26, 2012·The Breast : Official Journal of the European Society of Mastology·Xiaoyan DingBinghe Xu
Apr 23, 2011·Critical Reviews in Oncology/hematology·Peyman Hadji
Aug 21, 2013·Case Reports in Oncological Medicine·Ali Murat TatlıHasan Şenol Coşkun
Jun 15, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Terry L NgMark J Clemons